Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective randomised phase II trial of oral vinorelbine and cisplatin or pemetrexed and cisplatin in first line Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.

Next Previous
Search
Trial Profile

Prospective randomised phase II trial of oral vinorelbine and cisplatin or pemetrexed and cisplatin in first line Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemetrexed (Primary) ; Vinorelbine (Primary) ; Cisplatin
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NAVoTRIAL01; NAVoTRIAL1
  • Sponsors Pierre Fabre

    • Most Recent Events

    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 29 Sep 2012 Status changed from recruiting to completed, as reported in the abstract presented at ESMO.
    • 03 Mar 2012 This trial has been completed in Spain.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top